Puma Biotechnology マネジメント
マネジメント 基準チェック /44
Puma Biotechnologyの CEO はAlan Auerbachで、 Sep2010年に任命され、 の在任期間は 15.83年です。 の年間総報酬は$ 3.06Mで、 30.4%給与と69.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の13.84%を直接所有しており、その価値は$ 57.29M 。経営陣と取締役会の平均在任期間はそれぞれ8.1年と9.7年です。
主要情報
Alan Auerbach
最高経営責任者
US$3.1m
報酬総額
| CEO給与比率 | 30.41% |
| CEO在任期間 | 15.8yrs |
| CEOの所有権 | 13.8% |
| 経営陣の平均在職期間 | 8.1yrs |
| 取締役会の平均在任期間 | 9.7yrs |
経営陣の近況
Recent updates
ナラティブの更新 • Jun 06
PBYI: 2026 Revenue Guidance Will Likely Still Fail To Justify Pricing
Analysts have kept their $5.00 price target on Puma Biotechnology broadly aligned with prior estimates, reflecting only small adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E inputs in their valuation work. What's in the News Puma Biotechnology raised full year 2026 guidance, now expecting total revenue of US$222 million to US$229 million and net income of US$16 million to US$19 million, citing increased demand for NERLYNX.ナラティブの更新 • May 19
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology to reflect updated views on fair value at $5.00. This change is accompanied by revised assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple.分析記事 • May 15
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) earnings announcement last week didn't impress shareholders. However, our...分析記事 • May 11
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
A week ago, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) came out with a strong set of first-quarter numbers that could...ナラティブの更新 • Apr 28
PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing
Analysts have adjusted their price target on Puma Biotechnology slightly, with the updated fair value moving to $5.00. This reflects refreshed views on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions.ナラティブの更新 • Apr 11
PBYI: 2026 Profitability Guidance Will Likely Fail To Support Current Pricing
Analysts have slightly adjusted their price target on Puma Biotechnology, keeping fair value around $5.00 while fine tuning inputs such as discount rate, revenue growth, profit margin, and future P/E to reflect updated assumptions about the company’s risk profile and earnings potential. What's in the News Puma Biotechnology issued new earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million, with an expected net loss of US$8 million to US$10 million (company guidance).ナラティブの更新 • Mar 28
PBYI: 2026 Guidance Will Likely Fail To Justify Current Pricing
Analysts have modestly adjusted their price target on Puma Biotechnology, reflecting small refinements to assumptions around the discount rate, revenue growth, profit margins, and forward P/E rather than a major shift in the outlook. What's in the News Puma Biotechnology issued earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million (Key Developments).ナラティブの更新 • Mar 13
PBYI: Index Inclusion Will Likely Fail To Offset Weak Revenue Outlook
Analysts have trimmed their price target on Puma Biotechnology to $5.00 from $5.00 in response to updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E. These changes leave the fair value estimate effectively unchanged.ナラティブの更新 • Feb 26
PBYI: Index Addition And Refined Assumptions Will Still Limit Upside Potential
Analysts have adjusted their price target on Puma Biotechnology to reflect an updated fair value of $5.00, a slightly lower discount rate of 7.25%, almost unchanged revenue growth at about 97%, a stable profit margin near 11.02%, and a marginally different future P/E of roughly 13.33x, indicating a largely intact valuation framework with only fine tuning to their assumptions. What's in the News Puma Biotechnology, Inc.ナラティブの更新 • Feb 11
PBYI: Index Inclusion And Higher Multiple Will Likely Fail To Support Upside
Analysts have raised their price target on Puma Biotechnology to $5.00 from $3.50, citing updates to fair value estimates, discount rate assumptions, and expected future P/E levels. What's in the News Puma Biotechnology, Inc.ナラティブの更新 • Jan 26
PBYI: Higher 2025 Guidance And Index Addition Will Not Sustain Current Optimism
Analysts have slightly adjusted their price target on Puma Biotechnology, citing modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these changes translate into a small refinement in estimated fair value rather than a major reset in outlook.
ナラティブの更新 • Jan 12
PBYI: Higher 2025 Guidance And Index Inclusion Will Still Look Overpriced
Analysts have lifted their price targets on Puma Biotechnology, citing updates to their models that reflect a fair value estimate of $5.00, adjusted discount rates, revised revenue growth assumptions of about 1% instead of a 3% decline, higher projected profit margins of around 10% compared with about 3%, and a lower assumed future P/E multiple near 14 versus about 37. What's in the News Puma Biotechnology, Inc.ナラティブの更新 • Dec 26
PBYI: Raised 2025 Guidance Will Still Fail To Support Current Optimism
Analysts have modestly trimmed their price target on Puma Biotechnology to reflect a slightly lower future earnings multiple, even as estimates for fair value and long term growth remain largely unchanged. What's in the News Puma Biotechnology has been added to the NASDAQ Biotechnology Index, increasing its visibility among biotech-focused investors (index announcement).ナラティブの更新 • Dec 12
PBYI: 2025 Revenue Guidance Will Fail To Justify Current Optimism
Analysts have modestly adjusted their price target on Puma Biotechnology higher, now seeing slightly improved valuation support in light of stable fair value estimates and marginally lower perceived risk in the companys long term outlook. What's in the News Puma Biotechnology issued new fourth quarter 2025 guidance, projecting total revenue between $67 million and $70 million and net income of $9 million to $11 million (company guidance).分析記事 • Dec 09
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...ナラティブの更新 • Nov 27
PBYI: Rising Discount Rate Will Undermine Earnings Momentum In 2025
Analysts have slightly lowered their price target for Puma Biotechnology, citing marginal revisions in key financial estimates. This resulted in a new target of $3.50 per share, which remains unchanged from the previous assessment.分析記事 • Nov 13
Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit
The market shrugged off Puma Biotechnology, Inc.'s ( NASDAQ:PBYI ) solid earnings report. We think that investors might...Seeking Alpha • Nov 10
Puma Biotechnology: Step By Step In Making A Transition
Summary Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise. Read the full article on Seeking Alphaナラティブの更新 • Nov 09
PBYI: Rising Discount Rate And Weak Revenue Outlook Will Pressure Earnings
Analysts have raised their price target for Puma Biotechnology from $3.00 to $3.50, citing improved revenue growth projections and stronger expected profit margins. What's in the News Puma Biotechnology issued new earnings guidance for the fourth quarter of 2025, projecting total revenue between $67 million and $70 million, and net income between $9 million and $11 million (Key Developments).分析記事 • Oct 18
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have continued their recent momentum with a 26% gain in the last month...分析記事 • Sep 11
Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Aug 12
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market
NasdaqGS:PBYI 1 Year Share Price vs Fair Value Explore Puma Biotechnology's Fair Values from the Community and select...分析記事 • Aug 09
We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • May 20
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shareholders have had their patience rewarded with a 25% share price jump in...Seeking Alpha • Apr 11
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential
Summary Initiate coverage of Puma Biotechnology with a Hold rating due to limited near-term upside, competitive landscape, and uncertain pipeline outlook. NERLYNX adoption is hindered by side effects and competition, while alisertib is still in early development with modest expectations. Puma's cash runway may extend several years, but that could change with faltering revenues for NERLYNX, new drug additions, or other unforeseen pipeline developments. Legal issues and competitive pressures contribute to the cautious outlook, with no clear signs of growth or turnaround. Read the full article on Seeking Alpha分析記事 • Mar 10
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%
Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares have had a really impressive month, gaining 26% after a shaky period...
新しいナラティブ • Feb 09
Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains
Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.分析記事 • Jan 14
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Puma Biotechnology, Inc. ( NASDAQ:PBYI ) is...Seeking Alpha • Dec 16
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Summary Puma Biotechnology focuses on expanding neratinib sales and developing alisertib for breast and lung cancers, despite recent stock declines. Neratinib sales are stagnant, but the company remains stable financially. Alisertib shows early efficacy signals, with phase 2 trials ongoing, but its future success remains uncertain. Despite market skepticism, I maintain a "Buy" sentiment due to PBYI's favorable financial status and potential growth from alisertib. Read the full article on Seeking Alpha分析記事 • Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
When companies post strong earnings, the stock generally performs well, just like Puma Biotechnology, Inc.'s...分析記事 • Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 26% in...分析記事 • Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
To the annoyance of some shareholders, Puma Biotechnology, Inc. ( NASDAQ:PBYI ) shares are down a considerable 25% in...分析記事 • Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$24m |
| Dec 31 2025 | US$3m | US$931k | US$31m |
| Sep 30 2025 | n/a | n/a | US$37m |
| Jun 30 2025 | n/a | n/a | US$48m |
| Mar 31 2025 | n/a | n/a | US$38m |
| Dec 31 2024 | US$4m | US$904k | US$30m |
| Sep 30 2024 | n/a | n/a | US$23m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | US$15m |
| Dec 31 2023 | US$3m | US$878k | US$22m |
| Sep 30 2023 | n/a | n/a | US$4m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | US$5m |
| Dec 31 2022 | US$3m | US$852k | US$2k |
| Sep 30 2022 | n/a | n/a | US$10m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$18m | US$827k | -US$29m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$27m |
| Dec 31 2020 | US$4m | US$834k | -US$60m |
| Sep 30 2020 | n/a | n/a | -US$56m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$82m |
| Dec 31 2019 | US$4m | US$780k | -US$76m |
報酬と市場: Alanの 総報酬 ($USD 3.06M ) は、 US市場 ($USD 2.45M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Alanの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Alan Auerbach (56 yo)
15.8yrs
在職期間
US$3,062,337
報酬
Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman since October 4, 2011 and serves as its Chief Executive Officer, President and Secretary since September...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 15.8yrs | US$3.06m | 13.84% $ 57.3m | |
| CFO & Principal Accounting Officer | 7.7yrs | US$1.24m | 0.32% $ 1.3m | |
| Chief Regulatory Affairs | 8.5yrs | US$1.06m | 0.26% $ 1.1m | |
| Chief Accounting Officer | no data | データなし | データなし | |
| Senior Director of Investor Relations | 14.7yrs | データなし | データなし | |
| Senior Vice President of Marketing | 5.1yrs | データなし | データなし | |
| Senior Vice President of Sales | no data | データなし | データなし | |
| Senior Vice President of Clinical Operations | no data | データなし | データなし | |
| Senior Vice President of Clinical Development | less than a year | データなし | データなし | |
| Senior Vice President of Supply Chain & Manufacturing | no data | データなし | データなし | |
| Senior Vice President of Quality Assurance | no data | データなし | データなし |
8.1yrs
平均在職期間
57.5yo
平均年齢
経験豊富な経営陣: PBYIの経営陣は経験豊富で経験豊富です（平均在職期間は8.1年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 14.8yrs | US$3.06m | 13.84% $ 57.3m | |
| Lead Independent Director | 14.3yrs | US$173.08k | 0.062% $ 254.7k | |
| Independent Director | 8.4yrs | US$158.08k | 0.11% $ 439.0k | |
| Independent Director | 12.8yrs | US$173.08k | 0.065% $ 270.7k | |
| Independent Director | 4yrs | US$153.08k | 0.082% $ 340.2k | |
| Independent Director | 10.9yrs | US$165.58k | データなし | |
| Independent Director | 5yrs | US$155.58k | 0.13% $ 518.5k | |
| Independent Director | 6yrs | US$168.08k | 0.17% $ 706.2k |
9.7yrs
平均在職期間
63.5yo
平均年齢
経験豊富なボード: PBYIの 取締役会 は 経験豊富 であると考えられます ( 9.7年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/09 10:02 |
| 終値 | 2026/07/09 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Puma Biotechnology, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Paul Choi | Goldman Sachs |